Renalytix PLC
LSE:RENX

Watchlist Manager
Renalytix PLC Logo
Renalytix PLC
LSE:RENX
Watchlist
Price: 7.75 GBX Market Closed
Market Cap: 25.7m GBX
Have any thoughts about
Renalytix PLC?
Write Note

Intrinsic Value

RENX's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one RENX stock under the Base Case scenario is 14.35 GBX. Compared to the current market price of 7.75 GBX, Renalytix PLC is Undervalued by 46%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

RENX Intrinsic Value
14.35 GBX
Undervaluation 46%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Renalytix PLC

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for RENX cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about RENX?
Bearish
Neutral
Bullish

Fundamental Analysis

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Renalytix PLC

Provide an overview of the primary business activities
of Renalytix PLC.

What unique competitive advantages
does Renalytix PLC hold over its rivals?

What risks and challenges
does Renalytix PLC face in the near future?

Summarize the latest earnings call
of Renalytix PLC.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Renalytix PLC.

Provide P/S
for Renalytix PLC.

Provide P/E
for Renalytix PLC.

Provide P/OCF
for Renalytix PLC.

Provide P/FCFE
for Renalytix PLC.

Provide P/B
for Renalytix PLC.

Provide EV/S
for Renalytix PLC.

Provide EV/GP
for Renalytix PLC.

Provide EV/EBITDA
for Renalytix PLC.

Provide EV/EBIT
for Renalytix PLC.

Provide EV/OCF
for Renalytix PLC.

Provide EV/FCFF
for Renalytix PLC.

Provide EV/IC
for Renalytix PLC.

Show me price targets
for Renalytix PLC made by professional analysts.

What are the Revenue projections
for Renalytix PLC?

How accurate were the past Revenue estimates
for Renalytix PLC?

What are the Net Income projections
for Renalytix PLC?

How accurate were the past Net Income estimates
for Renalytix PLC?

What are the EPS projections
for Renalytix PLC?

How accurate were the past EPS estimates
for Renalytix PLC?

What are the EBIT projections
for Renalytix PLC?

How accurate were the past EBIT estimates
for Renalytix PLC?

Compare the revenue forecasts
for Renalytix PLC with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Renalytix PLC and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Renalytix PLC against its competitors.

Analyze the profit margins
(gross, operating, and net) of Renalytix PLC compared to its peers.

Compare the P/E ratios
of Renalytix PLC against its peers.

Discuss the investment returns and shareholder value creation
comparing Renalytix PLC with its peers.

Analyze the financial leverage
of Renalytix PLC compared to its main competitors.

Show all profitability ratios
for Renalytix PLC.

Provide ROE
for Renalytix PLC.

Provide ROA
for Renalytix PLC.

Provide ROIC
for Renalytix PLC.

Provide ROCE
for Renalytix PLC.

Provide Gross Margin
for Renalytix PLC.

Provide Operating Margin
for Renalytix PLC.

Provide Net Margin
for Renalytix PLC.

Provide FCF Margin
for Renalytix PLC.

Show all solvency ratios
for Renalytix PLC.

Provide D/E Ratio
for Renalytix PLC.

Provide D/A Ratio
for Renalytix PLC.

Provide Interest Coverage Ratio
for Renalytix PLC.

Provide Altman Z-Score Ratio
for Renalytix PLC.

Provide Quick Ratio
for Renalytix PLC.

Provide Current Ratio
for Renalytix PLC.

Provide Cash Ratio
for Renalytix PLC.

What is the historical Revenue growth
over the last 5 years for Renalytix PLC?

What is the historical Net Income growth
over the last 5 years for Renalytix PLC?

What is the current Free Cash Flow
of Renalytix PLC?

Discuss the annual earnings per share (EPS)
trend over the past five years for Renalytix PLC.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Renalytix PLC

Current Assets 28.3m
Cash & Short-Term Investments 26.3m
Receivables 776k
Other Current Assets 1.3m
Non-Current Assets 13.8m
PP&E 1.2m
Intangibles 12.5m
Other Non-Current Assets 51k
Current Liabilities 16.1m
Accounts Payable 2.9m
Accrued Liabilities 8.6m
Other Current Liabilities 4.6m
Non-Current Liabilities 7.5m
Long-Term Debt 7.5m
Efficiency

Earnings Waterfall
Renalytix PLC

Revenue
3.4m USD
Cost of Revenue
-2.7m USD
Gross Profit
701k USD
Operating Expenses
-43.1m USD
Operating Income
-42.4m USD
Other Expenses
-3.9m USD
Net Income
-46.2m USD

Free Cash Flow Analysis
Renalytix PLC

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

In Q3 fiscal 2024, Renalytix reported revenues of $535,000, down from $724,000 a year prior, with 806 tests processed. Notably, the company has diversified its testing locations, reducing dependency on Mount Sinai. Operating expenses decreased by 40% to $6.5 million, leading to a net loss of $7.7 million, improving from $12.1 million last year. Following the FDA approval of KidneyIntelX, the sales force achieved a 33% increase in test orders. Looking ahead, they expect to onboard the FDA-authorized version broadly in 2024, with pricing set at $950 per test.

What is Earnings Call?
Fundamental Scores

RENX Profitability Score
Profitability Due Diligence

Renalytix PLC's profitability score is 22/100. The higher the profitability score, the more profitable the company is.

Exceptional Revenue Growth Forecast
Positive Gross Profit
Positive 1-Year Revenue Growth
Declining ROE
22/100
Profitability
Score

Renalytix PLC's profitability score is 22/100. The higher the profitability score, the more profitable the company is.

RENX Solvency Score
Solvency Due Diligence

Renalytix PLC's solvency score is 63/100. The higher the solvency score, the more solvent the company is.

Negative Net Debt
Low D/E
Long-Term Solvency
Short-Term Solvency
63/100
Solvency
Score

Renalytix PLC's solvency score is 63/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

RENX Price Targets Summary
Renalytix PLC

There are no price targets for RENX.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for RENX?

Click here to dive deeper.

Dividends

Renalytix PLC
does not pay dividends
Shareholder Yield

Current shareholder yield for RENX is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

Renalytix PLC Logo
Renalytix PLC

Country

United Kingdom

Industry

Health Care

Market Cap

25.7m GBP

Dividend Yield

0%

Description

Renalytix Plc manufactures medical devices and equipment. The company is headquartered in Penarth, South Glamorgan. The company went IPO on 2018-11-06. The firm is focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care. The firm's diagnostic platform, KidneyIntelX, is designed to scale across kidney disease conditions beyond diabetic kidney disease. The firm is evaluating a range of new indications in chronic kidney disease, cardio-renal disease, chronic kidney disease in diverse populations and coronavirus disease (COVID)-related kidney disease. KidneyIntelX platform facilitates the identification and promotes the effective management of patients at risk of early-stage diabetic kidney disease (DKD), progression by combining diverse data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record (HER) using a proprietary algorithm to generate a unique patient risk score.

Contact

SOUTH GLAMORGAN
Penarth
Avon HSE, 19 Stanwell Road
+447748960970.0
renalytix.com

IPO

2018-11-06

Employees

-

Officers

CEO & Chairman
Mr. James R. McCullough M.B.A.
CTO & Executive Director
Mr. Fergus Fleming
Chief Medical Officer
Dr. Michael J. Donovan M.D., Ph.D.
President
Mr. Howard B. Doran Jr.
Interim CFO & Principal Accounting Officer
Mr. Joel R. Jung MBA
Company Secretary
Mr. Salim Gulamabbas Hamir F.C.A.

See Also

Discover More
What is the Intrinsic Value of one RENX stock?

The intrinsic value of one RENX stock under the Base Case scenario is 14.35 GBX.

Is RENX stock undervalued or overvalued?

Compared to the current market price of 7.75 GBX, Renalytix PLC is Undervalued by 46%.

Back to Top